FIVE PRIME ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FPRX and Encourages Investors to Contact the Firm
March 04, 2021 at 12:02 PM EST
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Amgen Inc. (NASDAQ: AMGN).
Click here to learn more and participate in the action.
On March 4, 2021, Five Prime announced that it had signed an agreement to be acquired by Amgen for approximately $1.9 billion. Pursuant to the merger agreement, Five Prime stockholders will receive $38 in cash for each share of Five Prime common stock owned. The deal is scheduled to close in the second quarter of 2021.
Bragar Eagel & Squire is concerned that Five Prime’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Five Prime’s stockholders.
If you own shares of Five Prime and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at firstname.lastname@example.org or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.: